AbbVie reports positive leukaemia/lymphoma study data for Imbruvica

AbbVie has announced the findings of three phase III clinical trials demonstrating the benefits offered by its cancer drug Imbruvica.

The RESONATE, RESONATE-2 and HELIOS studies assessed the therapy as a treatment for chronic lymphocytic leukaemia/small lymphocytic lymphoma patients with genomic abnormalities that put them at a higher risk of poor outcomes.

Improved complete and overall response rates were associated with Imbruvica in these three trials, as well as better progression-free survival at 24 months and overall survival at 30 months, when compared to alternate therapies.

Dr Danelle James, head of clinical science at AbbVie subsidiary Pharmacyclics, said: "We continue to investigate the use of Imbruvica in high-risk patients so that ideally they too can achieve better response rates and overall outcomes to treatment."

The drug functions by inhibiting a protein called Bruton's tyrosine kinase, a key molecule in the B cell receptor signalling complex that plays an important role in the survival and spread of malignant B cells.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.